Abstract: Field harvested culture mix is used to inoculate organic waste and produce an inoculated waste material, where the field harvested culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: Field harvested culture mix is used to inoculate organic waste and produce an inoculated waste material, where the field harvested culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: Wheat bran culture mix is used to inoculate organic waste and produce an inoculated waste material, where the wheat bran culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: Wheat bran culture mix is used to inoculate organic waste and produce an inoculated waste material, where the wheat bran culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: Wheat bran culture mix is used to inoculate organic waste and produce an inoculated waste material, where the wheat bran culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: Wheat bran culture mix is used to inoculate organic waste and produce an inoculated waste material, where the wheat bran culture mix includes soil derived microbes. The inoculated waste material is shredded to produce shredded inoculated waste material which is fermented the shredded inoculated waste material for at least 7 days. Contents from the fermenter are then transferred into a dewatering device to produce dewatered contents which are then separated into soluble and suspended products.

Abstract: The present disclosure concerns methods, compositions and apparatus for detecting pathogens and/or molecular markers. In a particular embodiment, the pathogen to be detected may be Mycobacterium bovis or any other Mycobacterium species that causes tuberculosis in a mammal. However, the disclosed methods are not limited and virtually any type of pathogen and/or molecular marker may be screened and detected. Preferred embodiments comprise reflex supplemental testing using the same assay at approximately 100% sensitivity and the highest possible corresponding sensitivity—in one example 70%. Such assay conditions, used iteratively, result in elimination of 70% of uninfected subjects for each round of testing. Use of 4 or more rounds of testing results in less than 1% error. Since only positive samples are retested, the methods provide a rapid, inexpensive and highly accurate way to detect infected subjects.

Abstract: A method and apparatus are described for image sensor optimization. According to an embodiment of the invention, a method comprises capturing an image with an image sensor, the image sensor comprising a plurality of pixels; obtaining an output relating to the image from a first pixel of the plurality of pixels; and normalizing the output from the first pixel to correlate with photon flux striking the image sensor.

Abstract: Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R?-Glu-Trp-R?.

Abstract: The present invention concerns methods and compositions relating to matrix arrays. In certain embodiments, the arrays are translucent. In other embodiments, the arrays are reconfigurable. In preferred embodiments, the arrays are translucent and reconfigurable. Reconfigurable arrays may be produced using small linker molecules, such as aptamers or affibodies, attached to the array substrate. Preferably, the small linker molecules bind to an IgG specific portion of antibodies. Such arrays may be used to detect any target that binds selectively or specifically to an IgG, allowing great flexibility of use. Translucent matrix arrays may utilize a translucent, colloidal form of nitrocellulose to coat the array substrate.

Abstract: The present invention concerns methods and compositions relating to matrix arrays. In certain embodiments, the arrays are translucent. In other embodiments, the arrays are reconfigurable. In preferred embodiments, the arrays are translucent and reconfigurable. Reconfigurable arrays may be produced using small linker molecules, such as aptamers or affibodies, attached to the array substrate. Preferably, the small linker molecules bind to an IgG specific portion of antibodies. Such arrays may be used to detect any target that binds selectively or specifically to an IgG, allowing great flexibility of use. Translucent matrix arrays may utilize a translucent, colloidal form of nitrocellulose to coat the array substrate.

Abstract: Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R′-Glu-Trp-R″ pharmaceutical preparation useful in subjects having autoimmune diseases.

Abstract: This invention provides analogs of L-Glu-L-Trp and methods of using them for immunomodulation and treatment of pathological neovascular conditions. The analogs include the substitution of a carbon atom for a nitrogen atom in the indole ring of tryptophan.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: This invention provides peptides of the formula R'-Glx-Glx-Lys-R" in which Glx is Glu or Gln. In particular, this invention provides the peptides Thr-Ala-Glu-Glu-Lys and Thr-Pro-Glu-Glu-Lys. This invention also provides pharmaceutical compositions comprising these peptides. The peptides of this invention are useful for immunomodulation.

Abstract: Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R'-Glu-Trp-R".

Abstract: This invention provides methods of modulating the immune system by administering peptides of the formula R'-Glx-Glx-Lys-R" (SEQ ID NO:1) in which Glx is Glu or Gln. In particular, this invention provides the use of peptides Thr-Ala-Glu-Glu-Lys (SEQ ID NO:34) and Thr-Pro-Glu-Glu-Lys (SEQ ID NO:33).

Abstract: This invention provides analogs of L-Glu-L-Trp and methods of using them for immunomodulation and treatment of pathological neovascular conditions. The analogs include the substitution of a carbon atom for a nitrogen atom in the indole ring of tryptophan.

Abstract: This invention concerns methods for prophylactic and therapeutic treatment of diseases responsive to the opening of potassium channels, peptides having potassium channel opener activities, and pharmaceutical compositions and kits comprising such peptides.